Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBT440 in Idiopathic Pulmonary Fibrosis
NCT02846324Phase 2Completed
- Sponsor
- Global Blood Therapeutics
- Start
- Jun 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of voxelotor in idiopathic pulmonary fibrosis (IPF), sponsored by Global Blood Therapeutics. Started Jun 2016; status: completed.
02
Drugs
voxelotor
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02846324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846324.